Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor

Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi, Francesco Massari

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios. A deeper knowledge of the molecular mechanisms that correlate with tumor development and progression has made this revolution possible. In this amazing era, novel challenges are awaiting us in the clinical management of metastatic RCC. Of these, the development of reliable criteria which are able to predict tumor response to treatment or primary and acquired resistance to systemic treatments still remain an unmet clinical need. Thanks to the availability of data provided by studies evaluating genomic assessments of the disease, this goal may no longer be out of reach. In this review, we summarize current knowledge about genomic alterations related to primary and secondary resistance to target therapy and immune-checkpoint inhibitors in RCC.

Original languageEnglish (US)
Article number830
JournalCancers
Volume11
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Renal Cell Carcinoma
Neoplasms
Therapeutics

Keywords

  • Acquired resistance
  • Immune-checkpoint inhibitors
  • mTOR
  • PD-1/PD-L1
  • Predictive markers
  • Primary resistance
  • Renal cell carcinoma
  • Target therapy
  • VEGF
  • VEGFR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mollica, V., Di Nunno, V., Gatto, L., Santoni, M., Scarpelli, M., Cimadamore, A., ... Massari, F. (2019). Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor. Cancers, 11(6), [830]. https://doi.org/10.3390/cancers11060830

Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor. / Mollica, Veronica; Di Nunno, Vincenzo; Gatto, Lidia; Santoni, Matteo; Scarpelli, Marina; Cimadamore, Alessia; Lopez-Beltran, Antonio; Cheng, Liang; Battelli, Nicola; Montironi, Rodolfo; Massari, Francesco.

In: Cancers, Vol. 11, No. 6, 830, 01.06.2019.

Research output: Contribution to journalReview article

Mollica, V, Di Nunno, V, Gatto, L, Santoni, M, Scarpelli, M, Cimadamore, A, Lopez-Beltran, A, Cheng, L, Battelli, N, Montironi, R & Massari, F 2019, 'Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor', Cancers, vol. 11, no. 6, 830. https://doi.org/10.3390/cancers11060830
Mollica, Veronica ; Di Nunno, Vincenzo ; Gatto, Lidia ; Santoni, Matteo ; Scarpelli, Marina ; Cimadamore, Alessia ; Lopez-Beltran, Antonio ; Cheng, Liang ; Battelli, Nicola ; Montironi, Rodolfo ; Massari, Francesco. / Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor. In: Cancers. 2019 ; Vol. 11, No. 6.
@article{c1e0846e5fbf47cfb6dde05670433486,
title = "Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor",
abstract = "The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios. A deeper knowledge of the molecular mechanisms that correlate with tumor development and progression has made this revolution possible. In this amazing era, novel challenges are awaiting us in the clinical management of metastatic RCC. Of these, the development of reliable criteria which are able to predict tumor response to treatment or primary and acquired resistance to systemic treatments still remain an unmet clinical need. Thanks to the availability of data provided by studies evaluating genomic assessments of the disease, this goal may no longer be out of reach. In this review, we summarize current knowledge about genomic alterations related to primary and secondary resistance to target therapy and immune-checkpoint inhibitors in RCC.",
keywords = "Acquired resistance, Immune-checkpoint inhibitors, mTOR, PD-1/PD-L1, Predictive markers, Primary resistance, Renal cell carcinoma, Target therapy, VEGF, VEGFR",
author = "Veronica Mollica and {Di Nunno}, Vincenzo and Lidia Gatto and Matteo Santoni and Marina Scarpelli and Alessia Cimadamore and Antonio Lopez-Beltran and Liang Cheng and Nicola Battelli and Rodolfo Montironi and Francesco Massari",
year = "2019",
month = "6",
day = "1",
doi = "10.3390/cancers11060830",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "6",

}

TY - JOUR

T1 - Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor

AU - Mollica, Veronica

AU - Di Nunno, Vincenzo

AU - Gatto, Lidia

AU - Santoni, Matteo

AU - Scarpelli, Marina

AU - Cimadamore, Alessia

AU - Lopez-Beltran, Antonio

AU - Cheng, Liang

AU - Battelli, Nicola

AU - Montironi, Rodolfo

AU - Massari, Francesco

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios. A deeper knowledge of the molecular mechanisms that correlate with tumor development and progression has made this revolution possible. In this amazing era, novel challenges are awaiting us in the clinical management of metastatic RCC. Of these, the development of reliable criteria which are able to predict tumor response to treatment or primary and acquired resistance to systemic treatments still remain an unmet clinical need. Thanks to the availability of data provided by studies evaluating genomic assessments of the disease, this goal may no longer be out of reach. In this review, we summarize current knowledge about genomic alterations related to primary and secondary resistance to target therapy and immune-checkpoint inhibitors in RCC.

AB - The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios. A deeper knowledge of the molecular mechanisms that correlate with tumor development and progression has made this revolution possible. In this amazing era, novel challenges are awaiting us in the clinical management of metastatic RCC. Of these, the development of reliable criteria which are able to predict tumor response to treatment or primary and acquired resistance to systemic treatments still remain an unmet clinical need. Thanks to the availability of data provided by studies evaluating genomic assessments of the disease, this goal may no longer be out of reach. In this review, we summarize current knowledge about genomic alterations related to primary and secondary resistance to target therapy and immune-checkpoint inhibitors in RCC.

KW - Acquired resistance

KW - Immune-checkpoint inhibitors

KW - mTOR

KW - PD-1/PD-L1

KW - Predictive markers

KW - Primary resistance

KW - Renal cell carcinoma

KW - Target therapy

KW - VEGF

KW - VEGFR

UR - http://www.scopus.com/inward/record.url?scp=85070222364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070222364&partnerID=8YFLogxK

U2 - 10.3390/cancers11060830

DO - 10.3390/cancers11060830

M3 - Review article

AN - SCOPUS:85070222364

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 6

M1 - 830

ER -